Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Preimplantation Genetic Testing Market analysis

The China Preimplantation Genetic Testing Market was valued at $34.6 Million in 2025 and projected to reach to $64.6 Million by 2030, representing a compound annual growth rate of 13.3%. China's preimplantation genetic testing market is poised for substantial growth through 2030, with the market expanding from $34.6 million in 2025 to $64.6 million by 2030.

China Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Preimplantation Genetic Testing Market Trends and Insights

  • This 13.3% compound annual growth rate significantly outpaces global trends, reflecting China's rising demand for advanced reproductive healthcare and genetic screening technologies.
  • China's growing middle class, increasing awareness of genetic disorders, and supportive regulatory environment are driving adoption of PGT among fertility clinics and patients seeking to reduce hereditary disease risks. The market in China is characterized by rapid technological advancement and expanding access to assisted reproductive technologies.
  • China's substantial population base and improving healthcare infrastructure create substantial opportunities for PGT service providers.
  • Between 2025 and 2030, China is expected to consolidate its position as a leading regional market, with enhanced clinical capabilities and increased investment in genetic testing infrastructure supporting sustained growth throughout the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 13.3% CAGR
  • Market Size, 2025 ~USD 34.6 Million
  • Forecast, 2030 ~USD 64.6 Million
  • Country China

China Preimplantation Genetic Testing Market Overview

Rapid Market Expansion :

China's PGT market is growing at 13.3% CAGR, significantly outpacing the global rate of 10.5%, driven by increasing adoption of advanced reproductive technologies and genetic screening among Chinese couples.

Rising Middle Class Demand :

China's expanding middle class and increasing disposable incomes are fueling demand for premium reproductive healthcare services, with PGT becoming increasingly accessible to affluent urban populations seeking genetic disease prevention.

Regulatory Support & Healthcare Investment :

Government initiatives promoting assisted reproductive technology (ART) and genetic screening, combined with substantial healthcare infrastructure investments, are creating favorable conditions for PGT market growth across major Chinese cities.

Demographic Pressures & Policy Changes :

China's relaxed reproductive policies and aging population concerns are driving couples to pursue advanced genetic testing, positioning PGT as a critical component of modern fertility treatment protocols in the country.

China Preimplantation Genetic Testing Market Dynamics

  • This trajectory reflects deepening healthcare modernization, increased consumer awareness of genetic screening benefits, and growing accessibility of PGT services in tier-1 and tier-2 cities.
  • The market benefits from China's large population base, rising fertility treatment demand, and improving clinical infrastructure. Key growth drivers include government support for reproductive health initiatives, rising healthcare spending, and shifting cultural attitudes toward genetic testing.
  • As technology costs decline and more fertility clinics adopt PGT capabilities, market penetration is expected to accelerate.
  • Strategic partnerships between international diagnostic companies and Chinese healthcare providers will further enhance service availability and standardization across the country..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • China's PGT market is valued at $34.6 million in 2025 and is forecast to reach $64.6 million by 2030, representing an accelerated 13.3% CAGR.
      • China's market growth rate substantially exceeds the global average of 10.5%, driven by rising healthcare spending and reproductive technology adoption.
      • China's expanding middle class and increased genetic disorder awareness are key drivers of PGT demand among fertility clinics and patients.
      • China's improving regulatory framework and healthcare infrastructure position the country as a leading regional market for genetic testing services through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      China Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES8.69.510.61213.615.517.720.313.7
      FERTILITY CLINICS24.5273033.7384348.855.613.1
      HOSPITALS6.26.77.48.29.210.311.613.112
      OTHER END USERS2.32.52.833.43.84.24.711.3
      TOTAL41.645.850.85764.272.682.493.613

      Target Audience

      • Fertility Clinic Operators : Chinese and international fertility clinics need market data to justify PGT service investments, benchmark against competitors, and understand patient demand trends across different regions and demographics.
      • Diagnostic & Biotech Companies : Genetic testing providers and biotech firms require China-specific market intelligence to develop localized PGT solutions, identify partnership opportunities, and plan market entry or expansion strategies.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive healthcare opportunities in China need validated market sizing, growth projections, and competitive analysis to support investment thesis development and due diligence.
      • Medical Device & Equipment Manufacturers : Companies supplying laboratory equipment and diagnostic instruments to Chinese fertility centers require market growth data and adoption trends to forecast demand and optimize distribution strategies.
      • Healthcare Policy & Government Bodies : Chinese healthcare regulators and policy makers benefit from comprehensive market analysis to inform reproductive health initiatives, resource allocation, and regulatory framework development for genetic testing services.

      Key Companies in the China Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for China's PGT sector with verified CAGR figures (13.3%), enabling accurate financial forecasting and investment decision-making for the 2025-2030 period.
      • Competitive Landscape Intelligence : Understand China-specific market dynamics, key players, regulatory environment, and competitive positioning to develop targeted market entry or expansion strategies in this high-growth reproductive healthcare segment.
      • Regional Growth Opportunity Assessment : Identify tier-1 and tier-2 city opportunities, demographic trends, and consumer behavior patterns unique to China that outpace global growth rates, informing resource allocation and market prioritization.
      • Strategic Partnership & Investment Guidance : Access actionable insights on collaboration opportunities with Chinese fertility clinics, diagnostic providers, and healthcare institutions to capitalize on the rapidly expanding $64.6M market by 2030.
      • Regulatory & Policy Framework Analysis : Gain comprehensive understanding of China's reproductive health policies, government support mechanisms, and healthcare regulations affecting PGT adoption and market accessibility for informed business planning.

      Frequently asked questions

      What is the current size of China's preimplantation genetic testing market?

      China's PGT market is valued at $34.6 million in 2025 and is expected to grow to $64.6 million by 2030.

      What is the projected growth rate for China's PGT market?

      China's PGT market is projected to grow at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2030.

      How does China's PGT market growth compare to global trends?

      China's 13.3% CAGR significantly outpaces the global average of 10.5%, indicating accelerated market expansion in the region.

      What factors are driving growth in China's preimplantation genetic testing market?

      Key drivers include China's rising middle class, increased awareness of genetic disorders, supportive regulatory environment, and expanding access to assisted reproductive technologies.

      What is the forecast market size for China's PGT market by 2030?

      China's PGT market is forecast to reach $64.6 million by 2030, nearly doubling from the 2025 baseline of $34.6 million.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status